Reading PDEX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PDEX free→Reading PDEX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PDEX free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality is fragile, indicating that reported profits may not be well-supported by cash. Management's recent track record has been fairly steady, while risk is high and the sector backdrop presents a headwind. Peer multiples imply a price roughly in line with where it trades (about fair); the read is fair, but weakening, as recent financials or earnings quality are weakening. Key factors to watch include guidance changes and performance of sector bellwethers, which could significantly impact PDEX's outlook. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $63.72. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $62 PDEX trades at 17× p/e, below its 20× p/e peer median. Our $62 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 0% near-term growth, in line with our forecast of about 9%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 0.61x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$213.
How much price usually moves either way.
On a bad day, this stock has moved -$519.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,532.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the health care sector's revenue growth speeds up, it could benefit Pro-Dex. This may improve investor sentiment.
Confirms:Health care sector revenue growth is speeding up again. It is moving toward 10% or more.
Disproves:Health care sector revenue growth slows below 5%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PDEX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On April 30, 2026, Pro-Dex, Inc. (the “Company”) is issuing a press release announcing its financial…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PDEX Pro-Dex, Inc. | Above typical Show detailsSector percentile: 93 of 100 | fair | high |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 93 of 100 | fair | elevated |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to continue the trend of revenue and operating income growth.
Newly stated in 2025-Q4. Revenue grew from $14.89M in 2025-Q1 to $19.95M in 2026-Q3, and operating income grew from $3.01M to $3.09M over the same period. The trajectory shows delivering on revenue growth, but operating income growth is limited.
“We expect fiscal 2026 to continue our trend of revenue and operating income growth.”
Management provided EPS guidance of $3.27 for the fiscal year ending June 30, 2026.
Stated in 3 of last 3 quarters. EPS guidance for fiscal year 2026 is $3.27. Net income for the nine months ended March 31, 2026, was $10.8 million, indicating progress towards the EPS target. The trajectory is delivering on EPS guidance.
Completed acquisition of Advanced Precision Machining to enhance manufacturing capabilities.
Newly stated in 2026-Q2. The acquisition of Advanced Precision Machining LLC was completed, aiming to enhance manufacturing capabilities. This strategic move is expected to support future growth, but its financial impact is yet to be reflected in the numbers.
“Pro-Dex completed its acquisition of Advanced Precision Machining LLC.”
Why it matters: If peers like Lilly or AbbVie show strong earnings, it may lift Pro-Dex's profile. It shows how the market views the sector.
Confirms one read:Lilly or AbbVie reports earnings growth above 15% year over year.
Confirms the other:Lilly or AbbVie reports earnings decline of 5% or more year over year.
Departure of Directors or Principal Officers, Election of Directors, Appointment of Principal Officers; Compensatory Arrangements of Principal Officers Compensation of Chief Financial Officer On March 23, 2026, pursuant to approval of the Compensation Committee of the Board of Directors of Pro-Dex, Inc. (“Pro-Dex” or the “Company”), Alisha K. Charlton, the Company’s Chief Financial Officer, had an increase in base salary from $247,200 to $257,000 per year effective with the Company’s next bi-…
Completion of Acquisition or Disposition of Assets. The disclosures contained in
Entry into a Material Definitive Agreement. Acquisition of Advance Precision Machining On February 9, 2026, Pro-Dex, Inc. (“Pro-Dex” or the “Company”) completed its acquisition of all the issued and outstanding membership interests (the “Acquisition”) of Advanced Precision Machining LLC, a California limited liability company (“APM”), resulting in APM becoming a wholly owned subsidiary of the Company. APM is engaged in the manufacture of various machined components serving customers in a vari…
of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On January 29, 2026, Pro-Dex, Inc. (the “Company”) is issuing a press release announcing its financia…
“Net income for the nine months ended March 31, 2026, was $10.8 million or $3.27 per diluted share.”
“Net income for the six months ended December 31, 2025, was $6.9 million or $2.07 per diluted share.”
“We are pleased with our first quarter results and excited to have resumed shipment of our largest customer’s next generation handpiece.”